NDI 5001
Alternative Names: NDI-5001Latest Information Update: 25 Jun 2024
At a glance
- Originator NephroDI Therapeutics
- Class Small molecules
- Mechanism of Action AMP activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetes insipidus
Most Recent Events
- 20 Jun 2024 NDI 5001 receives Orphan Drug status for Diabetes insipidus in USA before June 2024
- 20 Jun 2024 The US FDA grants Rare Pediatric Disease designation for NDI 5001 for the treatment of Diabetes insipidus before June 2024
- 20 Jun 2024 NephroDI Therapeutics plans clinical trial for Diabetes insipidus disorder later this year